Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00985933 · ClinicalTrials.gov registry record · Early Phase 1
The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers
A Early Phase 1 study of Healthy and Memory Impairment, sponsored by AstraZeneca.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00985933: Completed Early Phase 1 study of Healthy and Memory Impairment, sponsored by AstraZeneca.
NCT00985933 is a Early Phase 1 study of Healthy and Memory Impairment that has completed, run by AstraZeneca. The registered enrollment target is 20 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00985933, a Early Phase 1 study of Healthy and Memory Impairment, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess if ketamine will induce, in healthy volunteers, impairment of working memory and if the drug AZD8529 will block the effects of ketamine on working memory as assessed by functional magnetic resonance imaging (fMRI).
Conditions Studied
Interventions
- DRUG AZD8529
- DRUG Placebo to match AZD8529
Study Locations (1)
Connecticut
- Research Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-02 |
| Est. Completion | 2011-04 |
| Phase | Early Phase 1 |
What the finished NCT00985933 record still lists
NCT00985933 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which AZD8529 is the first listed.
NCT00985933 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00985933 about?
NCT00985933 is a clinical study titled "The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers". The purpose of this study is to assess if ketamine will induce, in healthy volunteers, impairment of working memory and if the drug AZD8529 will block the effects of ketamine on working memory as assessed by functional magnetic resonance imaging (fMRI).
What is the current status of trial NCT00985933?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2010-02. Estimated completion is 2011-04.
What conditions does trial NCT00985933 study?
This clinical trial studies the following conditions: Healthy, Memory Impairment.
What interventions are being tested in trial NCT00985933?
The interventions under investigation include: AZD8529 (DRUG), Placebo to match AZD8529 (DRUG).
Who is sponsoring clinical trial NCT00985933?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00985933 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00985933's enrollment target sits among peer trials
20 861st of 1090 higher than 194 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
RECRUITING · Early Phase 1
-
SV2A Density Cannabis Use Disorder
RECRUITING · Early Phase 1
-
CBD-Microglia PET Study
RECRUITING · Early Phase 1
-
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
- NCT01630850 · 20 participants · NA
Islet Transplantation in Patients With "Brittle" Type I Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia